I also attended the Melbourne briefing. A couple of additional...

I also attended the Melbourne briefing. A couple of additional nuggets MT dropped:

1. They are conducting pre-clinical animal work on other neurodegenerative diseases with protein aggregation pathology - Alzheimers, Parkinson's, etc - and anticipate announcing results before the end of the year. This activity is clearly aimed at further building PAA's valuation ahead of acquisition.

2. They have developed a liquid form of monepantel and MT alluded this could be used in the OLE study. This is interesting as liquid would be a better administration form than tablets for ALS patients who may have difficulty swallowing.

As a general comment, it was crystal clear that everything they are now doing is aimed at setting the company up for acquisition by BP with interest in neurodegenerative disease. As mentioned above, dog cancer, etc have been jettisoned as they are of no interest to such an acquirer.